We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Scientists working for pharmaceutical firm Eli Lilly found that, in 3,000 patients given the drug over the course of three years, the monthly jab more than doubled the risk of a deadly condition ...